These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 26312576)

  • 1. Effect of Growth Hormone Treatment on Fractures and Quality of Life in Postmenopausal Osteoporosis: A 10-Year Follow-Up Study.
    Krantz E; Trimpou P; Landin-Wilhelmsen K
    J Clin Endocrinol Metab; 2015 Sep; 100(9):3251-9. PubMed ID: 26312576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth hormone increases bone mineral content in postmenopausal osteoporosis: a randomized placebo-controlled trial.
    Landin-Wilhelmsen K; Nilsson A; Bosaeus I; Bengtsson BA
    J Bone Miner Res; 2003 Mar; 18(3):393-405. PubMed ID: 12619921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
    Liberman UA; Weiss SR; Bröll J; Minne HW; Quan H; Bell NH; Rodriguez-Portales J; Downs RW; Dequeker J; Favus M
    N Engl J Med; 1995 Nov; 333(22):1437-43. PubMed ID: 7477143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women.
    Holloway L; Kohlmeier L; Kent K; Marcus R
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1111-7. PubMed ID: 9100582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of supplementation of calcium and vitamin D on bone mineral density and bone mineral content in peri- and post-menopause women; a double-blind, randomized, controlled trial.
    Di Daniele N; Carbonelli MG; Candeloro N; Iacopino L; De Lorenzo A; Andreoli A
    Pharmacol Res; 2004 Dec; 50(6):637-41. PubMed ID: 15501704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older.
    Dawson-Hughes B; Harris SS; Krall EA; Dallal GE
    N Engl J Med; 1997 Sep; 337(10):670-6. PubMed ID: 9278463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
    Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
    Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Letter to the Editor: Comment on "Effect of Growth Hormone Treatment on Fractures and Quality of Life in Postmenopausal Osteoporosis: A 10-Year Follow-Up Study" by Kratz E., et al.
    Salvatori R
    J Clin Endocrinol Metab; 2015 Nov; 100(11):L107. PubMed ID: 26544657
    [No Abstract]   [Full Text] [Related]  

  • 9. [Long-term effects of 7-year growth hormone substitution on bone metabolism, bone density, and bone quality in growth hormone-deficient adults].
    Wilhelm B; Kann PH
    Med Klin (Munich); 2004 Oct; 99(10):569-77. PubMed ID: 15490072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.
    Lindsay R; Nieves J; Formica C; Henneman E; Woelfert L; Shen V; Dempster D; Cosman F
    Lancet; 1997 Aug; 350(9077):550-5. PubMed ID: 9284777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteodensitometry in healthy postmenopausal women.
    Prescrire Int; 2008 Apr; 17(94):68-72. PubMed ID: 18536138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
    Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
    Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
    J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strontium: new drug. Postmenopausal osteoporosis: too many unknowns.
    Prescrire Int; 2005 Dec; 14(80):207-11. PubMed ID: 16397977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone: Antifracture efficacy of growth hormone-confirmation at long last.
    Holmes D
    Nat Rev Endocrinol; 2015 Nov; 11(11):631. PubMed ID: 26391976
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study.
    Silverman SL; Shen W; Minshall ME; Xie S; Moses KH
    J Rheumatol; 2007 Jan; 34(1):140-4. PubMed ID: 17216681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate.
    Bruyere O; Roux C; Detilleux J; Slosman DO; Spector TD; Fardellone P; Brixen K; Devogelaer JP; Diaz-Curiel M; Albanese C; Kaufman JM; Pors-Nielsen S; Reginster JY
    J Clin Endocrinol Metab; 2007 Aug; 92(8):3076-81. PubMed ID: 17566094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to the Letter by Salvatori R.
    Krantz E; Trimpou P; Landin-Wilhelmsen K
    J Clin Endocrinol Metab; 2015 Nov; 100(11):L108. PubMed ID: 26544658
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.